32387-18-1

Usage

Uses

Used in Pharmaceutical Industry:
5-Bromo-1H-indole-3-trimethyl ethanone is used as a key intermediate in the synthesis of pharmaceuticals for its potential anticancer properties. It contributes to the development of drugs targeting various types of cancer by modulating multiple signaling pathways involved in tumor growth and progression.
Used in Organic Synthesis:
In the field of organic synthesis, 5-Bromo-1H-indole-3-trimethyl ethanone is utilized as a building block for the preparation of a wide range of indole derivatives. Its unique structure allows for the creation of various compounds with different biological activities and potential applications.
Used in Antimicrobial Applications:
5-Bromo-1H-indole-3-trimethyl ethanone is employed as an antimicrobial agent, demonstrating effectiveness against a variety of microorganisms. Its ability to inhibit microbial growth makes it a promising candidate for the development of new antimicrobial drugs and treatments.
Used in Anti-Inflammatory Research:
5-BroMo-1H-indole-3-triMethyl ethanone is also used in anti-inflammatory research, where its potential to modulate inflammatory pathways and reduce inflammation-related symptoms is explored. This makes it a valuable tool in the development of new anti-inflammatory drugs and therapies.
Used in Scientific Research:
5-Bromo-1H-indole-3-trimethyl ethanone is a valuable compound in scientific research, where its diverse range of biological activities is investigated. Researchers use 5-BroMo-1H-indole-3-triMethyl ethanone to study its effects on various biological processes and to develop new drugs and therapies based on its properties.

Upstream product

• 10075-50-0 5-bromo-1H-indole 
• 407-25-0 trifluoroacetic anhydride 

Downstream Products

• 1417717-57-7 2-(5-bromo-1H-indol-3-yl)-1,1,1-trifluoro-4-phenylbut-3-yn-2-ol 
• 1404537-13-8 C₃₁H₃₃N₇O₃*ClH 
• 1404533-19-2 sodium {3-[4-(4-butyryl-5-methyl-pyrazol-1-yl)phenylcarbamoyl]-5-cyano-indol-1-yl}acetate 
• 1404531-81-2 {3-[4-(4-butyryl-5-methyl-pyrazol-1-yl)phenylcarbamoyl]-5-cyano-indol-1-yl}acetic acid methyl ester 
• 1404532-70-2 {3-[4-(4-butyryl-5-methyl-pyrazol-1-yl)phenylcarbamoyl]-5-bromo-indol-1-yl}acetic acid methyl ester 

Relevant academic research and scientific papers

High-throughput screening of bioactive compounds via new catalytic reaction in the pooled mixture

To increase the chances of finding new candidate molecules with medicinal properties, while expending less resource and effort, the present study used pooled substrates as starting materials. A bisindole compound that showed inhibitory activity was then isolated from the mixture, and the activity was improved by optimizing the substituents on the indole skeleton.

DIMETHOXYPHENYL SUBSTITUTED INDOLE COMPOUNDS AS TLR7, TLR8 OR TLR9 INHIBITORS

Disclosed are compounds of Formula (I) or a salt thereof, wherein R1, R3, R4, R5, m, and n are defined herein. Also disclosed are methods of using such compounds as inhibitors of signaling through Toll-like receptor 7, or 8, or 9, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating inflammatory and autoimmune diseases.

Cell death inhibitor and novel compound

Provided is a cell-death inhibitor including, as an active ingredient thereof, a compound represented by formula (1), and/or a compound represented by formula (2). The cell-death inhibitor exhibits high cell-death inhibition activity.

Efficient Synthesis and Biological Activity of Novel Indole Derivatives as VEGFR-2 Tyrosine Kinase Inhibitors

A series of novel indole derivatives were synthesized as potent inhibitors for the vascular endothelial growth factor receptor 2 (VEGFR-2) tyrosine kinase. Among those, compound 10b demonstrated the highest growth inhibition rate of 66.7% against the VEGFR-2 tyrosine kinase at 10 μM which indicates that indole-benzothiazole might be the favorable structure. The binding mode of compound 10b with VEGFR-2 tyrosine kinase was evaluated by molecular docking.

N -[6-(4-Butanoyl-5-methyl-1 H -pyrazol-1-yl)pyridazin-3-yl]-5-chloro-1-[2-(4-methylpiperazin-1-yl)-2-oxoethyl]-1 H -indole-3-carboxamide (SAR216471), a Novel Intravenous and Oral, Reversible, and Directly Acting P2Y12 Antagonist

In the search of a potential backup for clopidogrel, we have initiated a HTS campaign designed to identify novel reversible P2Y12 antagonists. Starting from a hit with low micromolar binding activity, we report here the main steps of the optimization process leading to the identification of the preclinical candidate SAR216471. It is a potent, highly selective, and reversible P2Y12 receptor antagonist and by far the most potent inhibitor of ADP-induced platelet aggregation among the P2Y12 antagonists described in the literature. SAR216471 displays potent in vivo antiplatelet and antithrombotic activities and has the potential to differentiate from other antiplatelet agents.

NOVEL BIS-INDOLIC DERIVATIVES, A PROCESS FOR PREPARING THE SAME AND THEIR USES AS A DRUG

The present invention relates to novel bis-indolic derivatives, processes for their preparation, and their potential use as new antibacterial drugs.

BIS-INDOLIC DERIVATIVES, A PROCESS FOR PREPARING THE SAME AND THEIR USES AS A DRUG

The present invention relates to novel bis-indolic derivatives, processes for their preparation, and their potential use as new antibacterial drugs.

DERIVATIVES OF N-[(1H-PYRAZOL-1-YL)ARYL]-1H-INDOLE OR 1H-INDAZOLE-3-CARBOXAMIDE, PREPARATION THEREOF AND APPLICATIONS THEREOF IN THERAPEUTICS

The present invention relates to compounds corresponding to formula (I): in which: A represents a divalent aromatic radical; X represents a —CH— group or a nitrogen atom; R1 represents a (C1-C4)alkyl or a (C1-C4)alkoxy; R2 represents a group Alk; R3 represents a hydroxyl or a group —NR7R8; R4 represents a hydrogen atom, a halogen atom, a cyano, a phenyl, a group Alk, a group OAlk or a group —NR9R10; R5 represents a hydrogen atom, a halogen atom or a group Alk; R6 represents a hydrogen atom, a halogen atom, a cyano, a group —COOAlk or a —CONH2 group.

DERIVATIVES OF N- [(1H-PYRAZOL-1-YL) ARYL] - 1H - INDOLE OR 1H - INDAZOLE - 3 - CARBOXAMIDE, THEIR PREPARATION AND THEIR USE AS P2Y12 ANTAGONISTS

The present invention relates to compounds corresponding to formula (I) and their use as P2Y12 antagonists for the treatment of cardiovascular diseases.

Synthesis and anticancer activity of 5-(3-indolyl)-1,3,4-thiadiazoles

A series of 5-(3-indolyl)-2-substituted-1,3,4-thiadiazoles 5a-m were synthesized and their cytotoxicity analyzed against six human cancer cell lines. The reaction of indole-3-carboxylic acid 3 with aryl or heteroaryl hydrazides afforded the N,N′-diacylhydrazines 4, which upon treatment with Lawesson's reagent resulted in the formation of indolyl-1,3,4-thiadiazoles 5a-m in good yields. Indolyl-1,3,4-thiadiazole 5m with 4-benzyloxy-3-methoxyphenyl and 5-bromo indolyl substituents is the most active in suppressing the growth of cancer cells (IC50 1.5 μM, PaCa2). The compounds 5b, 5e and 5h bearing C-2 substituent as benzyl, 3,4-dimethoxyphenyl and 4-benzyloxy-3- methoxyphenyl, respectively, have shown significant cytotoxicity against multiple cancer cell lines. Introduction of 4-dimethylamino (5d and 5k) and 3,4,5-trimethoxy (5l) groups in the C-2 phenyl ring induced selectivity against MCF7 and MDA-MB-231 cancer cell lines (compounds 5d, 5k and 5l).